uBiome Appoints Dr. Emeran Mayer, MD, World-Renowned Gastroenterologist and Neuroscientist, to its Medical Advisory Board
SAN FRANCISCO, Nov. 23, 2018
SAN FRANCISCO, Nov. 23, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announces the addition of Dr. Emeran Mayer, MD, Executive Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Mayer will bring to uBiome his expertise on the connections between the digestive and nervous systems and the implications on health and disease. The appointment will help uBiome continue its advancement in human microbiome research.
"Dr. Mayer's extensive research on chronic pain and the brain gut health axis is an immense benefit to uBiome's interest in understanding how intestinal inflammation alters the structure and function of the brain," says Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. "We are honored to have Dr. Mayer on uBiome's Medical Advisory Board and look forward to the insights he will bring."
In addition to his position at the G. Oppenheimer Center for Neurobiology of Stress and Resilience, Dr. Mayer is also a co-director of the CURE: Digestive Diseases Research Center at UCLA and a professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA. Dr. Mayer's work includes investigating the role of the gut microbiota brain interactions in emotion regulation, chronic visceral pain, and obesity. He is a recognized expert in functional GI disorders, and has published 320 peer reviewed scientific articles, including 100 chapters and reviews, co-edited four books. He is the author of the widely respected book, "The Mind-Gut Connection: How the Hidden Conversation Within Our Bodies Impacts or Mood, Our Choices, and Our Overall Health."
About joining uBiome's Medical Advisory Board, Dr. Mayer said, "I am excited to contribute to uBiome's visions about the important role of the gut microbiome in influencing the brain in health and disease, and to join the distinguished scientists and physicians on the company's advisory board."
In addition to Dr. Mayer, the uBiome Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company's Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children's Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.